ERYTECH Pharma completes the enrollment of patients in its Phase I clinical trial in pancreatic cancer Post author:admERY Post published:June 27, 2011 Post category:Newsroom ERYTECH Pharma has just completed the enrollment of patients in a Phase I clinical trial with its flagship product for pancreatic cancer, Graspa®. You Might Also Like ERYTECH to Present Two Posters at AACR March 17, 2016 ERYTECH Announces $7.85 Million Registered Direct Offering December 14, 2021 ERYTECH to Present Results from Phase I Trial of eryaspase in ALL and New Pre-clinical Data at AACR 2018 April 12, 2018
ERYTECH to Present Results from Phase I Trial of eryaspase in ALL and New Pre-clinical Data at AACR 2018 April 12, 2018